TIPPS* [30] Rodger
|
2013
|
Canada, Multinational N = 292
|
Thrombophilia + previous high risk criteria
|
Dalteparin 5000 IU to 20 wks then 10,000 IU to 36 wks vs no Dalteparin
|
PE, SB, abruption, SGA <10th percentile
|
Yes
|
FRUIT [20] de Vries
|
2012
|
Netherlands, Multinational N = 139
|
Prior early onset PE (n = 107) and/or SGA <10th percentile (n = 94)
|
Dalteparin 5000 IU + ASA vs ASA
|
PE prior to 34 weeks GA
|
Yes
|
HAPPY [25] Martinelli
|
2012
|
Italy, Multi-center N = 135
|
Prior PE (n = 52), prior loss >15 weeks (n = 49), prior SGA <10th percentile (n = 28) or prior abruption (n = 5)
|
Nadroparin 3800 IU vsno Nadroparin
|
PE, Loss >15 weeks GA, SGA <10thpercentile and/or abruption
|
Yes
|
NOH-PE [21] Gris
|
2011
|
France, Single center N = 224
|
Prior severe PE (n = 224)
|
Enoxaparin 4000 IU + ASA vs ASA
|
PE, SB, abruption, SGA <5th percentile
|
Yes
|
NOH-AP [24] Gris
|
2010
|
France, Single center N = 160
|
Prior abruption (n = 160; 70 with PE)
|
Enoxaparin 4000 IU+/−ASA vs +/−ASA
|
PE, SB, abruption, SGA <5thpercentile
|
Yes
|
Rey [23]
|
2009
|
Canada, Multi-center N = 116
|
Prior early PE (n = 60), prior abruption (n = 16), prior SGA <5th percentile (n = 21), loss >12 weeks (n = 17)
|
Dalteparin 5000 IU+/−ASA vs +/−ASA
|
PE, SB, abruption, SGA <5th percentile
|
Yes
|
Mello [22]
|
2005
|
Italy, Single center N = 80
|
Prior PE with ACE DD (n = 80)
|
Dalteparin 5000 IU vsno Dalteparin
|
PE, SGA <10th percentile
|
Unable to contact
|